CAR T-cell

Advertisement
DocWire News EditorsASCO 2022 | September 21, 2023
A study presented at the 2022 American Society of Clinical Oncology Annual Meeting found that an autologous CD7 chimeric ...
Read More
Kerri FitzgeraldSNMMI | September 21, 2023
The approach may help inform clinical decision-making early in treatment.
DocWire News EditorsHOPA Annual Conference 2022 | November 15, 2022
Chimeric antigen receptor (CAR) T-cell therapy is a promising new treatment option for certain oncology patient ...
DocWire News EditorsOncology | December 27, 2021
Background aims: Efforts to safely and effectively treat acute myeloid leukemia (AML) by targeting a single ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
The chimeric antigen receptor (CAR) T-cell therapy axicabtagene ciloleucel (axi-cel) demonstrated significant and ...
DocWire News EditorsOncology | April 27, 2023
Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, looks into the future of ...
DocWire News EditorsOncology | April 27, 2023
Noopur Raje, MD, Director of the Multiple Myeloma Program at Massachusetts General Hospital, describes the new ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 30, 2023
Pivotal trials that supported Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
In a single-arm phase I/II study, infusion with CT103A, a novel fully human B-cell maturation antigen (BCMA)-targeted ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
Chimeric antigen receptor (CAR) T-cell therapy is a potentially life-saving option for patients with hematologic ...
Rebecca AraujoOncology | December 17, 2021
This week on DocWire, we covered the latest breaking research from the American Society of Hematology (ASH) 2021 Annual ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 6, 2023
Pivotal trials that supported Food and Drug Administration (FDA) approval of chimeric antigen receptor (CAR) T-cell ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
Black Americans were severely under-represented in clinical trials that supported FDA approvals of chimeric antigen ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | December 9, 2022
Patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL) who received second-line treatment with ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | August 31, 2023
A study reported updated results from the CARTITUDE-1 trial, which previously showed that cilacabtagene autoleucel ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
Prescribing chemotherapy is not a universal practice of advanced practice providers (APPs) in the oncology community, ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
According to new research presented during the 2021 ASH Annual Meeting, circulating tumor DNA (ctDNA) accurately ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 3, 2023
Chimeric antigen receptor (CAR) T-cell therapy with lisocabtagene maraleucel (liso-cel) significantly improved ...
DocWire News EditorsASH Annual Meeting and Exposition 2021 | April 19, 2023
Despite advances in novel therapies, survival rates remain poor for patients with relapsed/refractory aggressive B-cell ...
Manni Mohyuddin, MDOncology | August 30, 2023
Greetings, DocWire News readers. I attempt here to summarize the most important updates from the 2021 International ...
Advertisement
Advertisement
Advertisement
Latest News

March 18, 2025